Kayahan, N. Et Al. 2021. Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer. TURKISH JOURNAL OF MEDICAL SCIENCES , vol.51, no.4 , 1727-1732.

Kayahan, N., Karaca, M., SATIŞ, H., YAPAR, D., & ÖZET, A., (2021). Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer. TURKISH JOURNAL OF MEDICAL SCIENCES , vol.51, no.4, 1727-1732.

Kayahan, Neslihan Et Al. "Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer," TURKISH JOURNAL OF MEDICAL SCIENCES , vol.51, no.4, 1727-1732, 2021

Kayahan, Neslihan Et Al. "Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer." TURKISH JOURNAL OF MEDICAL SCIENCES , vol.51, no.4, pp.1727-1732, 2021

Kayahan, N. Et Al. (2021) . "Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer." TURKISH JOURNAL OF MEDICAL SCIENCES , vol.51, no.4, pp.1727-1732.

@article{article, author={Neslihan Kayahan Et Al. }, title={Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer}, journal={TURKISH JOURNAL OF MEDICAL SCIENCES}, year=2021, pages={1727-1732} }